Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy.
Immune-related adverse events
Immunotherapy
Mean platelet volume
Non-small cell lung cancer
Overall survival
Platelets
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
02
09
2022
accepted:
29
01
2023
medline:
15
6
2023
pubmed:
17
2
2023
entrez:
16
2
2023
Statut:
ppublish
Résumé
Patients treated with immune checkpoint inhibitors (ICIs) may not response to treatment and are at risk for immune-related adverse events (irAEs). Platelet function has been linked to both oncogenesis and immune evasion. We studied the association between the change in mean platelet volume (MPV), platelet count, survival, and the risk of developing irAEs in patients with metastatic non-small cell lung cancer (NSCLC) who have received first-line ICI. In this retrospective study, delta (∆) MPV was defined as the difference between cycle 2 and baseline MPV. Patient data were collected via chart review, and Cox proportional hazard and Kaplan-Meier method were used to assess the risk and estimate median overall survival. We identified 188 patients treated with first-line pembrolizumab, with or without concurrent chemotherapy. There were 80 (42.6%) patients received pembrolizumab monotherapy, and 108 (57.4%) received pembrolizumab in combination with platinum-based chemotherapy. Patients whose MPV (∆MPV ≤ 0) decreased had hazard ratio (HR) = 0.64 (95% CI 0.43-0.94) for death with p = 0.023. Patients with ∆MPV ≤ - 0.2 fL (median), there was a 58% increase in the risk of developing irAE (HR = 1.58, 95% CI 1.04-2.40, p = 0.031). Thrombocytosis at baseline and cycle 2 was associated with shorter OS with p = 0.014 and 0.039, respectively. Change in MPV after 1 cycle of pembrolizumab-based treatment was significantly associated with overall survival as well as the occurrence of irAEs in patients with metastatic NSCLC in the first-line setting. In addition, thrombocytosis was associated with poor survival.
Identifiants
pubmed: 36795122
doi: 10.1007/s00262-023-03392-9
pii: 10.1007/s00262-023-03392-9
doi:
Substances chimiques
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2067-2074Subventions
Organisme : NIH HHS
ID : P30CA016058
Pays : United States
Organisme : NIH HHS
ID : P30CA016058
Pays : United States
Organisme : NIH HHS
ID : P30CA016058
Pays : United States
Organisme : NIH HHS
ID : P30CA016058
Pays : United States
Organisme : NIH HHS
ID : P30CA016058
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Gandhi L et al (2018) Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 378(22):2078–2092
doi: 10.1056/NEJMoa1801005
pubmed: 29658856
Mok TSK et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819–1830
doi: 10.1016/S0140-6736(18)32409-7
pubmed: 30955977
Reck M et al (2016) Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375(19):1823–1833
doi: 10.1056/NEJMoa1606774
pubmed: 27718847
Antonia SJ et al (2017) Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 377(20):1919–1929
doi: 10.1056/NEJMoa1709937
pubmed: 28885881
Qiu Z et al (2019) Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. Exp Hematol Oncol 8(1):19
doi: 10.1186/s40164-019-0143-z
pubmed: 31463163
pmcid: 6706908
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. New Engl J Med 378(2):158–168
doi: 10.1056/NEJMra1703481
pubmed: 29320654
Couey MA et al (2019) Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7(1):165
doi: 10.1186/s40425-019-0645-6
pubmed: 31269983
pmcid: 6609357
Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133–150
doi: 10.1038/s41568-019-0116-x
pubmed: 30755690
pmcid: 6705396
Webb NJ et al (1998) Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci 94(4):395–404
doi: 10.1042/cs0940395
Selheim F, Holmsen H, Vassbotn FS (2002) Identification of functional VEGF receptors on human platelets. FEBS Lett 512(1):107–110
doi: 10.1016/S0014-5793(02)02232-9
pubmed: 11852061
Lindemann S et al (2001) Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 154(3):485–490
doi: 10.1083/jcb.200105058
pubmed: 11489912
pmcid: 2196422
Rachidi S et al (2017) Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol 2(11):eaai7911
doi: 10.1126/sciimmunol.aai7911
pubmed: 28763790
pmcid: 5539882
Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5):576–590
doi: 10.1016/j.ccr.2011.09.009
pubmed: 22094253
pmcid: 3487108
Riesenberg BP et al (2019) Cutting edge: targeting thrombocytes to rewire anticancer immunity in the tumor microenvironment and potentiate efficacy of PD-1 blockade. J Immunol 203(5):1105–1110
doi: 10.4049/jimmunol.1900594
pubmed: 31358658
Metelli A et al (2020) Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β. Sci Transl Med 12(525):eaay4860
doi: 10.1126/scitranslmed.aay4860
pubmed: 31915300
pmcid: 7814995
Handtke S et al (2019) Role of platelet size revisited—function and protein composition of large and small platelets. Thromb Haemost 119(03):407–420
doi: 10.1055/s-0039-1677875
pubmed: 30727004
Li N et al (2017) Elevated mean platelet volume predicts poor prognosis in colorectal cancer. Sci Rep 7(1):10261
doi: 10.1038/s41598-017-11053-y
pubmed: 28860547
pmcid: 5579290
Matowicka-Karna J et al (2013) Platelets and inflammatory markers in patients with gastric cancer. Clin Dev Immunol 2013:401623
doi: 10.1155/2013/401623
pubmed: 23554823
pmcid: 3608177
Korniluk A et al (2019) Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediat Inflamm 2019:9213074
doi: 10.1155/2019/9213074
Hsiehchen D et al (2022) Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology 11(1):2017162
doi: 10.1080/2162402X.2021.2017162
pubmed: 35003896
pmcid: 8741287
Martini C et al (2020) Platelets disrupt vasculogenic mimicry by cancer cells. Sci Rep 10(1):5869
doi: 10.1038/s41598-020-62648-x
pubmed: 32246008
pmcid: 7125143
Kanikarla-Marie P et al (2018) Platelet metabolism and other targeted drugs potential impact on immunotherapy. Front Oncol 8:107
doi: 10.3389/fonc.2018.00107
pubmed: 29732316
pmcid: 5919962
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867
doi: 10.1038/nature01322
pubmed: 12490959
pmcid: 2803035
Wood LS (2019) Immune-related adverse events from immunotherapy: incorporating care step pathways to improve management across tumor types. J Adv Pract Oncol 10(Suppl 1):47–62
pubmed: 33014517
pmcid: 7522659
Davies M, Duffield EA (2017) Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther 6:51–71
doi: 10.2147/ITT.S141577
pubmed: 28894725
pmcid: 5584920
Assi HA et al (2020) Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy. Future Sci OA 6(7):FSO581
doi: 10.2144/fsoa-2020-0021
pubmed: 32802390
pmcid: 7421541
Haddad TC et al (2022) Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. Cancer Immunol Immunother 71(5):1157–1165
doi: 10.1007/s00262-021-03068-2
pubmed: 34618180
Ma Y et al (2021) Prognostic significance of thrombocytosis in lung cancer: a systematic review and meta-analysis. Platelets 32(7):919–927
doi: 10.1080/09537104.2020.1810653
pubmed: 32892682
Zhuo Y, Lin L, Zhang M (2017) Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis. Platelets 28(6):560–566
doi: 10.1080/09537104.2016.1246712
pubmed: 27848258
Ye Q et al (2019) Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis. J Gynecol Oncol 30(1):e5
doi: 10.3802/jgo.2019.30.e5
pubmed: 30479089
Rachidi S et al (2019) Platelet count correlates with stage and predicts survival in melanoma. Platelets 30(8):1042–1046
doi: 10.1080/09537104.2019.1572879
pubmed: 30759042
Foster CC et al (2021) Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer 127(24):4565–4573
doi: 10.1002/cncr.33780
pubmed: 34547103
Haratani K et al (2018) Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer. JAMA Oncol 4(3):374–378
doi: 10.1001/jamaoncol.2017.2925
pubmed: 28975219
Eggermont AMM et al (2020) Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol 6(4):519–527
doi: 10.1001/jamaoncol.2019.5570
pubmed: 31895407
pmcid: 6990933
Freeman-Keller M et al (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886–894
doi: 10.1158/1078-0432.CCR-15-1136
pubmed: 26446948
Li M et al (2019) Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. J Cancer Res Clin Oncol 145(10):2541–2546
doi: 10.1007/s00432-019-02982-4
pubmed: 31367835
pmcid: 6751277
Bagley SJ et al (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1–7
doi: 10.1016/j.lungcan.2017.01.013
pubmed: 28285682
Bai R et al (2020) Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 8(1):34
doi: 10.1186/s40364-020-00209-0
pubmed: 32864131
pmcid: 7450548